Peptides in aging and regeneration research – a guide to anti-aging peptides

Contextual disclaimer
The following article is educational in nature and is a review of published scientific literature on peptides studied in the context of biological aging, tissue regeneration and central nervous system function. Most of the studies cited come from in vitro and animal models. Where data from human clinical trials exist, this fact is clearly stated. The text does not constitute medical advice or a protocol for use in humans. Peptides from the One Peptides catalog are intended for Research Use Only.
In 1973, Loren Pickart, conducting experiments on liver regeneration in old rats, isolated a fragment of three amino acids from human plasma albumin: glycyl-histidyl-lysine. The molecule, today known as GHK, turned out to be much more biologically active after binding to the copper(II) ion – the GHK-Cu complex triggered mechanisms in the tissues typical of young organisms. This discovery launched an entire branch of research on signal peptides in the context of aging.
Half a century later, we have a bibliography containing thousands of experimental works on anti-aging peptides, neuropeptides and tissue bioregulators. Some of these molecules – Epithalon, Semax, Selank – come from the Russian school of peptidology developed in St. Petersburg and Moscow since the 1970s. Others – GHK-Cu, oxytocin as a modulator of social bonding – arose from Western research. They have one thing in common: peptides act as signals regulating the cell’s genomic response, not as substrates or simple receptor agonists.
This article collects the current state of knowledge about anti-aging and wellness peptides. We discuss the regenerative mechanisms common to tissue repair peptides in more detail in the overview article about regenerative peptides.

Contents

1. Hallmarks of aging – the molecular context of anti-aging peptidology
2. GHK-Cu — copper peptide in tissue regeneration research
3. Epithalon – pineal peptide and its role in telomere research
4. Oxytocin – a social neuropeptide in neuroscience
5. Nootropic Peptides – Semax and Selank
6. Methodological limitations of research on anti-aging peptides
7. Wellness peptides analytical specification
8. FAQ
9. Bibliography

1. Hallmarks of aging – molecular context of anti-aging peptidology

In 2013, a group led by Carlos López-Otín published the conceptual work “The hallmarks of aging”, defining nine molecular hallmarks of cellular aging. The updated 2023 version expanded the list to twelve traits, adding three new ones: macroautophagy defects, low-grade chronic inflammation, and microbiome dysbiosis (López-Otín, Blasco, Partridge, Serrano, Kroemer, 2023). A framework approach to these processes organizes where peptides can actually interfere with biological aging.

1.1 Twelve molecular hallmarks of aging

Characteristic	Mechanism	Peptide capture point
Genomic instability	Accumulation of DNA damage	Transcription bioregulators (Epithalon)
Shortening telomeres	Erosion of chromosome ends during divisions	Direct telomerase activation in models (Epithalon)
Epigenetic changes	DNA and histone methylation drift	Modulation of gene expression (bioregulatory peptides)
Loss of proteostasis	Accumulation of misfolded proteins	Very limited peptide data
Nutrient detection disorders	Dysregulation of mTOR, AMPK, IGF-1	Indirectly via GLP-1
Mitochondrial dysfunction	Decrease in bioenergetic efficiency	Single signals – requires validation
Cellular senescence (senescence)	Permanent cell cycle arrest	GHK-Cu – SASP modulation in models
Stem cell exhaustion	Decrease in pool and regenerative potential	GHK-Cu — increase in the expression of stem cell markers
Intercellular communication disorders	Cytokine and hormone dysregulation	Signal peptides – most of the class discussed
Chronic inflammation (inflammaging)	Low-grade inflammation	GHK-Cu, nootropic peptides (anti-neuroinflammatory effect)
Microbiome dysbiosis	Disturbance of the composition and function of the microbiota	There is no direct data for the peptides in question
Macroautophagy defects	Decrease in autophagy activity	Single observations in models

1.2 Peptides as transcription modulators

A common feature of most anti-aging peptides is their effect at the transcriptional, not metabolic, level. GHK-Cu in Pickart and Margolina’s (2018) study modulated the expression of 31% of all human genes in microarray analyzes – an effect much greater than most conventional pharmacology. Epithalon in the work of Khavinson’s group changes the DNA methylation profile and indirectly activates telomerase. The mechanism of anti-aging peptides is more like “directing the genome’s response” than classic receptor stimulation.
This feature explains why peptides in this class act at very low (nanomolar) concentrations and why their effects are often pleiotropic – a single molecule triggers a network of parallel responses.

2. GHK-Cu – copper peptide in tissue regeneration research

GHK is a tripeptide glycyl-L-histidyl-L-lysine, naturally present in human plasma at a concentration of approximately 200 ng/ml in young people, decreasing to 80 ng/ml after the age of 60 (Pickart and Margolina, 2018). The biological activity of the peptide depends on complexation with the copper(II) ion – GHK itself has a limited effect, GHK-Cu is a functional form.
For a full overview of cosmetic peptides ? GHK-Cu, Matrixyl, Argireline, collagen peptides ? in the skin-care context, see the guide to peptides for skin.

2.1 Molecular mechanism

The GHK-Cu complex has three overlapping functions in tissues:

• Regenerative signaling – activates skin fibroblasts, stimulates the synthesis of collagen I and III, decorin, glycosaminoglycans. In in vitro experiments, it also increased elastin synthesis and improved the architecture of the extracellular matrix.
• Copper-led antioxidant – chelates free copper ions (which themselves generate reactive oxygen species in Fenton reactions) and modulates superoxide dismutase activity.
• Gene expression modulator – Microarray analyzes have shown modulation of over 4,000 genes, including increased expression of regenerative genes and decreased expression of pro-inflammatory genes (Pickart et al., 2017).

2.2 Status of research on dermal use

GHK-Cu is the best documented regenerative peptide in a dermatological context. Clinical studies on humans have shown:

• Reduction of wrinkle depth in a 12-week topical application (Leyden et al., 2002 – conference presentation at the 60th Annual Meeting AAD; not published as a full peer-reviewed article, financed by cosmetics manufacturers)
• Increase in epidermal thickness measured by ultrasound after 12 weeks
• Improving skin tone and reducing sun discoloration

Most trials were conducted in small groups (n=20–60) and involved topical application, not systemic administration. In animal models – particularly rat models of diabetic wound healing – GHK-Cu accelerates wound closure by 30–40% compared to controls.

2.3 Other research directions

Outside of dermatology, GHK-Cu is tested in models:

• Pulmonary fibrosis – Zhou and colleagues demonstrated reduced accumulation of type I and III collagen in bleomycin-induced experimental fibrosis in mouse models.
• Peripheral nerve regeneration – rat models suggest accelerated reinnervation in transected sciatic nerves.
• Cellular senescence – the peptide modulated the phenotype of old cells in human fibroblast cultures, partially reducing the SASP (senescence-associated secretory phenotype) signature.

For a complete literature review with molecular mechanisms and specific research models, see the dedicated article GHK-Cu in Skin Research – Literature Review in the Knowledge Base.

2.4 Peptide specification

GHK-Cu is a peptide with a molecular weight of 340.8 Da (copper-free form of GHK) or 402.9 Da (complex with Cu²⁺). It is relatively stable in aqueous solutions at neutral pH, but requires protection from light and low temperature. The full reconstitution protocol is discussed in guide to laboratory practice.

3. Epithalon – pineal peptide and its role in telomere research

Epithalon (also known as Epitalon and AEDG) is a tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was isolated by Vladimir Khavinson’s team at the Institute of Bioregulation and Gerontology in Saint Petersburg as a synthetic analogue of the epithalamin peptide – a pineal fraction that has been shown to have life-extending effects in animal studies.

3.1 Mechanism and hypothesized function

Khavinson and his colleagues hypothesized that Epithalon acts as a “bioregulatory peptide” — a short peptide hypothesized to penetrate the nuclear membrane and interact directly with DNA. This mechanism remains proposed by Khavinson’s group, but has not been independently confirmed by structural biochemical methods. Mechanisms in the literature include:

• Telomerase activation – in cell cultures of human fetal fibroblasts (telomerase-negative at baseline), Epithalon induced the expression of the hTERT catalytic subunit, telomerase activity and telomere elongation; cells continued to divide beyond the 44th passage in the original work (Khavinson, Bondarev, Butyugov, 2003 Bull Exp Biol Med 135(6):590-592)
• Modulation of promoter methylation – impact on the epigenetic regulation of the expression of genes related to the response to stress and DNA repair
• Induction of gene expression typical of younger cells – a change in the expression profile in the direction characteristic of younger individuals was observed in mouse models

3.2 Animal studies – lifespan

The most frequently cited works come from Anisimov’s group and showed in a mouse model (CBA mice, female):

• Life expectancy increased by approximately 24% in the group receiving Epithalon in a cyclic protocol
• Reduction of spontaneous carcinogenesis
• Delayed oestropause

Studies by Khavinson’s group on 266 elderly people (long-term cyclic administration) suggested a reduction in mortality in the experimental group during the observation period of 6–12 years. However, these trials do not meet the standards of modern clinical trials (lack of a double-blind trial with an appropriate placebo, heterogeneous control groups) and their results are the subject of discussion in the gerontological literature.

3.3 Critical Limitations

It should be clearly noted that:
⚠️ The results of research on life extension by Epithalon come mainly from the work of one research group (Khavinson/Anisimov’s team), published mainly in Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (low-point magazines). Independent replications by Western groups are limited, and the methodology of some human studies (no double-blind, no placebo, heterogeneity of control groups) does not meet current ICH-GCP standards. Class of evidence for effects in humans: D. Conclusions about anti-aging effects remain in the experimental hypothesis phase.
For a full review of available data, methodological controversies and replication signals, see the dedicated article Epithalon and telomeres – what we know from animal studies.

4. Oxytocin – a social neuropeptide in neuroscience

Oxytocin is a nonapeptide (9 amino acids) synthesized in the supraoptic and paraventricular nuclei of the hypothalamus, stored in the posterior lobe of the pituitary gland. Classically known for its role in uterine contractions and lactation, the discovery of its neuromodulatory role in the brain has opened up an entirely new line of research.

4.1 Receptor and distribution

Oxytocin receptor (OXTR) is a class A G protein-coupled receptor. It is abundant in brain areas involved in the processing of social signals: the amygdala, ventral striatum, prefrontal cortex, and brainstem nuclei. The distribution of the receptor explains why oxytocin is a neuropeptide with such a strong influence on social behavior.

4.2 Social functions – what the research says

Research on oxytocin has gone through several phases:

• Discovery phase (1990s–2000s) – work on prairie voles (a monogamous species) showed that oxytocin is necessary for forming mate bonds. OXTR blocking substances prevented vapor formation.
• Extrapolation phase (2005–2015) — numerous human studies with intranasal administration of oxytocin suggested increased trust, eye contact, emotion recognition, and reduced social anxiety.
• Criticism and replication phase (2015–present) – Independent replications of many key experiments produced weaker results or did not confirm observations. The topic remains actively researched, but the initial optimism has been revised.

The contemporary picture of oxytocin’s role in social neuroscience is more nuanced than it was 10 years ago. The peptide modifies the processing of social stimuli in a contextual manner – it increases empathy towards the in-group, but in some studies it also increased out-group bias. The mechanism is real, but its effects are less clear than initially suggested.

4.3 State of research in clinical disorders

Clinical trials of oxytocin are ongoing in the context of autism (trials with intranasal administration in children with autism spectrum disorder – ambiguous results), schizophrenia (in terms of negative symptoms), and anxiety disorders. None of the uses have achieved registration as a drug in major jurisdictions.

4.4 Specifications and Stability

Oxytocin as a peptide is sensitive to hydrolysis in an aqueous environment and requires storage of the lyophilisate at a temperature below zero. After reconstitution in bacteriostatic water, stability reaches 14–28 days in a refrigerator at 2–8°C.

5. Nootropic Peptides – Semax and Selank

Semax and Selank are two nootropic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and 1990s. Both are synthetic derivatives of natural regulatory peptides – Semax is an analogue of ACTH(4-10), Selank is an analogue of tuftsin.

5.1 Semax – ACTH analogue without hormonal activity

The Semax sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first five amino acids correspond to the ACTH fragment, but the additional C-terminal Pro-Gly-Pro fragment stabilizes the peptide against proteolytic degradation and – importantly – eliminates corticotropic activity. Semax does not stimulate the adrenal glands.
Mechanisms of action documented in the literature:

• Modulation of BDNF and NGF expression – in in vitro and in vivo models, Semax increases the expression of brain neurotrophic factor and nerve growth factor (Dolotov et al., 2006)
• Neuroprotective effect in ischemia models – in rat models of closed middle cerebral artery occlusion, Semax reduces the volume of the infarct area
• Modulation of the dopamine and serotonin systems – effects observed by studies of monoamine metabolism in selected brain areas

In clinical practice in the Russian Federation, Semax is registered as a nootropic drug. It remains an investigational peptide in the European Union and the USA – its therapeutic status has not been confirmed by registration agencies.

5.2 Selank – an analogue of tuftsin with anxiolytic action

The Selanku sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four amino acids correspond to tuftsin (an immunomodulatory peptide derived from an IgG fragment). C-terminal Pro-Gly-Pro has a stabilizing function – this is a typical procedure of the Russian school of peptidology, also used in Semax.
The main mechanism of Selanku in the literature:

• Modulation of the GABAergic system – Selank increases the expression of GABA-A receptor subunits in the cortex and hippocampus of animal models
• Anxiolytic effect without sedation – in behavioral tests (open field, elevated plus maze), Selank showed an anxiety-reducing effect, but without reducing motor activity
• BDNF modulation – an effect similar to Semax, although weaker
• Effect on enkephalinases – possible modulation of the opioid system

Selank in the Russian Federation is used in the treatment of anxiety disorders. Outside of this market, it remains a research peptide.

5.3 Semax vs Selank – what are the pharmacological differences?

Characteristic	Semax	Selank
Source sequence	ACTH(4-10)	Tuftsin
Main layout	Dopamine, serotonergic	GABAergic
Performance profile	Activating, nootropic	Anxiolytic, mildly activating
BDNF modulation	Strong	Moderate
Registered in	Russian Federation – nootropics	Russian Federation – Anxiolytic

A full review of comparative research on both peptides and nootropic research methodology can be found in the dedicated article Nootropic peptides – Semax vs Selank in research.

6. Methodological limitations of research on anti-aging peptides

The field of anti-aging peptidology suffers from several systemic methodological problems, which, if ignored, lead to overinterpretation of available data. Any reading of literature in this area requires awareness of these limitations.

6.1 Publication geography and the issue of replication

Much of the research on Epithalon, Semax and Selank has been published in Russian-language journals or in English-language journals with a predominance of authors from one research group (especially Khavinson syndromes for bioregulators). Independent replications by Western groups are limited. This does not invalidate the results, but it lowers their epistemic importance relative to research that meets the full rigor of a multilaboratory.

6.2 Animal models vs. extrapolation to humans

Most of the peptides discussed in this guide have data from animal models – most commonly rats and mice. Extrapolation to humans is risky for several reasons:

• Time scale of aging – effects observed in mice over a 24-month cycle must be extrapolated to an 80-year cycle in humans, which introduces significant uncertainties
• Pharmacokinetic profile – Peptides have very different half-lives in different species
• Genetic homogeneity of models vs. heterogeneity of the human population

6.3 Short observation cycles vs. long aging processes

Anti-aging is a long-term phenomenon by nature. An experiment lasting 28 days is incompatible with processes that have been developing for decades. Most markers of serum aging—methylation changes, transcriptomic signatures, senescence markers—require months or years of follow-up to be interpretable.

6.4 Proteolysis and bioavailability

Peptides are susceptible to proteolytic degradation in the gastrointestinal tract and plasma. The choice of route of administration (intranasal, sublingual, subcutaneous) is critical – most study models used extraoral administration, which limits the applicability of the results to specific experimental protocols.

7. Analytical specification of wellness peptides

7.1 Quality requirements

Anti-aging and wellness peptides in the One Peptides catalog meet the following analytical requirements:

Parameter	Standard	Method
Purity (peptide content)	≥98%	Reverse phase HPLC
Molecular mass identity	Compliance with the theoretical M.W.	Mass spectrometry (MS)
Moisture of the lyophilisate	≤5%	Karl Fischer
Endotoxins	≤1 EU/mg	LAL test
Sterility	Compliance with USP <71>	Sterility test

Each vial is marked with a batch number associated with a certificate of analysis (COA). The full methodology for assessing peptide purity is discussed in the guide to identifying high-quality research peptides and in the article HPLC vs MS – methods for analyzing peptide purity.

7.2 Stability after reconstitution

Peptide	Water solubility	Stability after reconstitution (2-8°C)
GHK-Cu	Good (with light protection)	14–28 days
Epithalon	Very good	21–28 days
Oxytocin	Good (pH sensitive)	14–21 days
Semax	Very good	28 days
Selank	Very good	28 days

General Indications – Detailed reconstitution protocols can be found in the Laboratory Practice Guide.

7.3 Certificate verification

Analytical documents (HPLC chromatogram, MS spectrum, Karl Fischer report, LAL test) can be downloaded from the website quality tests and certificates. For research teams, full QC documentation is available upon request.

FAQ

Bibliography

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2023). Hallmarks of aging: An expanding universe
2. Pickart L, Margolina A (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data
3. Pickart L, Vasquez-Soltero JM, Margolina A (2017). The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline
4. Leyden JJ, Grove G, Stephens TJ, Finkey MB, Appa Y, Barkovic S (2002). Skin care benefits of copper peptide containing facial cream. Conference abstract, Proceedings of the 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, February 22-27, 2002. (note: conference presentation, not peer-reviewed publication in JAAD; financed by cosmetics manufacturers)
5. Zhou X, Li X, Zhang B, et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation. Life Sci. PMID: 31809714
6. Khavinson VKh, Bondarev IE, Butyugov AA (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 135(6):590-592. PMID: 12937682
7. Anisimov VN, Khavinson VKh (2009). Peptide bioregulation of aging: results and prospects. Biogerontology.
8. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analogue of ACTH(4-10), regulates BDNF and trkB expression in the rat hippocampus. Brain Res. PMID: 16996037
9. Kolomin TA, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides
10. Bartz JA, Zaki J, Bolger N, Ochsner KN (2011). Social effects of oxytocin in humans: context and person matter
11. Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B (2021). Advances in the field of intranasal oxytocin research

More articles from this cluster: full longevity overview.